S'abonner

Enteral Feeding during Indomethacin and Ibuprofen Treatment of a Patent Ductus Arteriosus - 23/07/13

Doi : 10.1016/j.jpeds.2013.01.057 
Ronald Clyman, MD 1, 2, , Andrea Wickremasinghe, MD 1, 2, Nami Jhaveri, MD 1, 2, Denise C. Hassinger, MD 3, Joshua T. Attridge, MD 4, Ulana Sanocka, MD 5, Richard Polin, MD 5, Maria Gillam-Krakauer, MD 6, Jeff Reese, MD 6, Mark Mammel, MD 7, Robert Couser, MD 7, Neil Mulrooney, MD 7, Toby D. Yanowitz, MD 8, Matthew Derrick, MD 9, Priya Jegatheesan, MD 10, Michele Walsh, MD 11, Alan Fujii, MD 12, Nicolas Porta, MD 13, William A. Carey, MD 14, Jonathan R. Swanson, MD 3

Ductus Arteriosus Feed or Fast with Indomethacin or Ibuprofen (DAFFII) Investigators

  A list of the DAFFII Investigators is available at www.jpeds.com (Appendix).

1 Department of Pediatrics, University of California San Francisco, San Francisco, CA 
2 Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA 
3 Department of Pediatrics, Morristown Medical Center, Morristown, NJ 
4 Department of Pediatrics, University of Virginia, Charlottesville, VA 
5 Department of Pediatrics, Columbia University Medical Center, New York, NY 
6 Department of Pediatrics, Vanderbilt University, Nashville, TN 
7 Department of Pediatrics, Children's Hospitals and Clinics of Minnesota-Minneapolis, Saint Paul, MN 
8 Department of Pediatrics, University of Pittsburgh, Pittsburgh, PA 
9 Department of Pediatrics, Northshore University Health System, Evanston, IL 
10 Department of Pediatrics, Santa Clara Valley Medical Center, San Jose, CA 
11 Department of Pediatrics, Case Western Reserve University, Cleveland, OH 
12 Department of Pediatrics, Boston University Medical Center, Boston, MA 
13 Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL 
14 Department of Pediatrics, Mayo Clinic, Rochester, MN 

Reprint requests: Ronald Clyman, MD, Box 0544, HSW 1408, University of California, San Francisco, 513 Parnassus Ave, San Francisco, CA 94143-0544.

Abstract

Objective

To test the hypothesis that infants who are just being introduced to enteral feedings will advance to full enteral nutrition at a faster rate if they receive “trophic” (15 mL/kg/d) enteral feedings while receiving indomethacin or ibuprofen treatment for patent ductus arteriosus.

Study design

Infants were eligible for the study if they were 231/7-306/7 weeks' gestation, weighed 401-1250 g at birth, received maximum enteral volumes ≤60 mL/kg/d, and were about to be treated with indomethacin or ibuprofen. A standardized “feeding advance regimen” and guidelines for managing feeding intolerance were followed at each site (N = 13).

Results

Infants (N = 177, 26.3 ± 1.9 weeks' mean ± SD gestation) were randomized at 6.5 ± 3.9 days to receive “trophic” feeds (“feeding” group, n = 81: indomethacin 80%, ibuprofen 20%) or no feeds (“fasting [nil per os]” group, n = 96: indomethacin 75%, ibuprofen 25%) during the drug administration period. Maximum daily enteral volumes before study entry were 14 ± 15 mL/kg/d. After drug treatment, infants randomized to the “feeding” arm required fewer days to reach the study's feeding volume end point (120 mL/kg/d). Although the enteral feeding end point was reached at an earlier postnatal age, the age at which central venous lines were removed did not differ between the 2 groups. There were no differences between the 2 groups in the incidence of infection, necrotizing enterocolitis, spontaneous intestinal perforation, or other neonatal morbidities.

Conclusion

Infants required less time to reach the feeding volume end point if they were given “trophic” enteral feedings when they received indomethacin or ibuprofen treatments.

Le texte complet de cet article est disponible en PDF.

Keyword : BPD, NEC, npo, PDA


Plan


 Supported by Gerber Foundation, National Institutes of Health/National Center for Research Resources-Clinical & Translational Science Institute (UL1 RR024131 and UL1TR000445), and a gift from the Jamie and Bobby Gates Foundation. The authors declare no conflicts of interest.
 Registered with ClinicalTrials.gov: NCT00728117.


© 2013  Mosby, Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 163 - N° 2

P. 406 - août 2013 Retour au numéro
Article précédent Article précédent
  • Dopamine-Resistant Hypotension and Severe Retinopathy of Prematurity
  • Melissa Catenacci, Shogo Miyagi, Andrea C. Wickremasinghe, Sarah Scarpace Lucas, Alejandra G. de Alba Campomanes, William V. Good, Ronald I. Clyman
| Article suivant Article suivant
  • Achieving Targeted Pulse Oximetry Values in Preterm Infants in the Delivery Room
  • Bheru Gandhi, Wade Rich, Neil Finer

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.